ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Selective Bcl-2 Inhibition for Induction of Mixed Chimerism and Renal Allograft Tolerance without Myelosupression

G. Lassiter1, T. Hirose1, H. Sasaki1, D. Ma1, T. Oura1, A. Dehnadi1, A. Cosimi1, P. Cippa2, T. Fehr3, T. Kawai1

1Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, 2Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland, 3Division of Nephrology, University of Zurich, Zurich, Switzerland

Meeting: 2021 American Transplant Congress

Abstract number: 576

Keywords: B cells, Mixed chimerism, T cells, Tolerance

Topic: Basic Science » Tolerance / Immune Deviation

Session Information

Session Name: Tolerance / Immune Deviation

Session Type: Poster Abstract

Session Date & Time: None. Available on demand.

Location: Virtual

*Purpose: Immunologic tolerance of renal allograft has been achieved by induction of hematopoietic chimerism through donor bone marrow transplantation (DBMT). The myeloablative and genetic toxicity associated with DBMT conditioning hampers widespread application of tolerance protocols. To this end, we have recently shown that the addition of selective BCL-2 inhibition with Venetoclax (Vtx) to our nonmyeloablative conditioning regimen can promote chimerism and allograft tolerance without myelosuppression. To establish the Vtx-based regimen for clinical application, the necessity of all aspects of the protocol for combined kidney and bone marrow transplantation was evaluated individually.

*Methods: Cynomolgus monkeys received various regimens which included low dose total body irradiation (TBI), local TI and ATG pre-CKBMT, followed by a short course of anti-CD154 mAb and Cyclosporine. The study groups consisted of 6 arms. Group A and B received no Vtx, but 3GyTBI and 1.5Gy TBI. Groups C,D,E and F all received Vtx but 1.5Gy TBI, no TBI, no TI, or no CoB, respectively.

*Results: All recipients of the conventional regimen, Group A, achieved chimerism and long-term allograft tolerance but experienced severe transient pancytopenia. With reduced TBI (1.5Gy) without Vtx, all recipients failed to develop chimerism and ¾ rejected by day 167. By adding Vtx, all three recipients achieved excellent chimerism (Fig. 1) and renal allograft tolerance without pancytopenia. Without TBI or CoB, all recipients failed to develop chimerism and rejected kidney allografts. Without TI, all three recipients failed to achieve tolerance despite successful development of chimerism. In this group, early repopulation of recent thymic emigrants and naive T cells were observed.

*Conclusions: TBI dose was reduced by adding Vtx, leading to successful chimerism and allograft tolerance without myelosuppression. Minimal TBI, TI, and CoB appeared to be essential in the protocol with selective Bcl-2 inhibition.

 border=

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Lassiter G, Hirose T, Sasaki H, Ma D, Oura T, Dehnadi A, Cosimi A, Cippa P, Fehr T, Kawai T. Selective Bcl-2 Inhibition for Induction of Mixed Chimerism and Renal Allograft Tolerance without Myelosupression [abstract]. Am J Transplant. 2021; 21 (suppl 3). https://atcmeetingabstracts.com/abstract/selective-bcl-2-inhibition-for-induction-of-mixed-chimerism-and-renal-allograft-tolerance-without-myelosupression/. Accessed May 9, 2025.

« Back to 2021 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences